Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prolactin: The Third Hormone in Breast Cancer

Frontiers in Endocrinology(2022)10.3389/fendo.2022.910978Source: DataRank Database

Prolactin: The Third Hormone in Breast Cancer is a research paper published in Frontiers in Endocrinology (2022). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access43 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 4.77)OA: goldTopics (52)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Kathleen A. O’Leary,Linda A. Schuler ORCID

Live enrichment

PubMed:35784527 PMC:PMC9244687 OpenAlex:https://openalex.org/W4282976740

NCI NIH HHS

Grant: P30 CA014520

NCI NIH HHS

Grant: R01 CA179556

National Institutes of Health

Grant: 3R01CA179556-02S1

Matrix density promotes pro-tumorigenc hormone actions in breast cancer

National Institutes of Health

Grant: 5P30CA014520-18

CANCER CENTER SUPPORT

FWCI

4.77

Citation Percentile

1.0%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fendo.2022.910978/pdf

GOLDhttps://www.frontiersin.org/articles/10.3389/fendo.2022.910978/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fendo.2022.910978/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fendo.2022.910978/full

journalhttps://doi.org/10.3389/fendo.2022.910978

Fields of Study

Growth Hormone and Insulin-like Growth FactorsCancer Risks and FactorsEstrogen and related hormone effectsMedicine0301 basic medicine0303 health sciences03 medical and health sciencesBreast NeoplasmsDisease ProgressionFemaleHumansInfant, NewbornLactationProlactinProspective Studies

MeSH Terms

Breast NeoplasmsFemaleHumansInfant, NewbornLactationProlactinProspective StudiesDisease Progression

Keywords

ProlactinBreast cancerLactationMedicineDiseaseHormoneBioinformaticsCancerMammary glandInternal medicinePhysiologyEndocrinologyOncologyBiologyPregnancymammary cancerTriple Negative Breast CancerLuminal Breast CancerHer2+ Breast CancerProlactin (Prl)Stat 5 Transcription FactorInfant, NewbornBreast NeoplasmsRC648-665Diseases of the endocrine glands. Clinical endocrinologyDisease ProgressionHumansFemaleProspective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers

10.6084/m9.figshare.22622494.v1figshare

Additional file 1 of Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers

10.6084/m9.figshare.22622494figshare

Prolactin: The Third Hormone in Breast Cancer

FAIR Checklist

Authors (2)

Funding (4 grants)

Impact

Open Access

Topics

Linked Datasets (2)

Annotations (Europe PMC)